# Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain

> **NCT07159243** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** HL-1186
- **DRUG:** HL-1186
- **DRUG:** HL-1186 placebo

## Key facts

- **NCT ID:** NCT07159243
- **Lead sponsor:** Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07159243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07159243, "Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07159243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*